Generic Oncology Drugs Market by Drug Class, Therapy Type, Cancer Type, Route Of Administration, End User - Global Forecast 2025-2030- Product Image

Sale

Generic Oncology Drugs Market by Drug Class, Therapy Type, Cancer Type, Route Of Administration, End User - Global Forecast 2025-2030

Report
195 Pages
October 2024
Region: Global
360iResearch™
ID: 6017361

UP TO €665EUR$697USD£557GBP OFF until Dec 31^st 2024

The Generic Oncology Drugs Market grew from USD 35.94 billion in 2023 to USD 38.74 billion in 2024. It is expected to continue growing at a CAGR of 7.06%, reaching USD 57.97 billion by 2030.

Generic oncology drugs refer to non-branded medications used in cancer treatment, possessing the same active ingredients, strength, and dosage form as branded versions. These drugs are crucial for reducing treatment costs and improving accessibility to cancer care globally. Their necessity stems from the ever-increasing cancer prevalence and the need for cost-effective treatments to ensure wider patient access. They are mainly applied in chemotherapy, targeted therapy, and hormone therapy, addressing various cancer types like breast, lung, and colorectal cancers. End-use encompasses hospitals, clinics, and ambulatory surgical centers where these drugs fulfill significant therapeutic needs.

Market growth is influenced by the rising cancer incidence, supportive government initiatives for generic drug manufacturing, and a growing aging population. Cost-effectiveness and patent expirations of major oncology drugs open substantial growth avenues. Noteworthy opportunities arise from increasing healthcare expenditure in emerging economies, the shift towards personalized medicine, and biosimilar developments. Companies should focus on strategic partnerships to explore niche markets and invest in advanced drug formulation technologies to maintain competitive advantage.

However, market expansion faces challenges like stringent regulatory norms, intense competition from branded drugs, and the complexity of generic drug manufacturing. Limited awareness and misconceptions regarding generic drugs in developing regions also hinder growth potential. Overcoming these barriers requires robust patient and clinician education efforts and streamlining regulatory pathways for faster approvals.

Innovation can be driven in areas like nanoparticle drug delivery systems, enhanced bioavailability techniques, and the development of multi-targeted therapies to address chemotherapy resistance. Research aiming at producing generics for newer cancer treatments expands market scope and fuels growth. The generic oncology drug market exhibits a dynamic yet challenging landscape, with ample opportunities for companies adept at navigating regulatory frameworks and demonstrating cost-value efficiencies, ensuring affordable cancer management and expansive reach to underserved populations.

Understanding Market Dynamics in the Generic Oncology Drugs Market

The Generic Oncology Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.

Market Drivers
- Rising prevalence of cancer globally increasing the demand for generic oncology drugs
- Government initiatives and funding boost for generic cancer drug research and development
- Escalating healthcare costs drive the shift towards cost-effective generic oncology solutions
- Increasing patent expiries of blockbuster oncology drugs paving the way for generics transition
Market Restraints
- Stringent patent laws and intellectual property challenges hindering generic oncology drug entry
- Supply chain vulnerabilities and raw material scarcity affecting generic oncology drug production
Market Opportunities
- Innovative technologies transforming generic oncology drugs market and enhancing therapeutic outcomes
- Strategic partnerships and collaborations enhancing research and development in generic oncology medications
- Regulatory advancements and expedited approval pathways driving growth in the generic oncology sector
Market Challenges
- Competition from branded drugs and intellectual property issues impacting the generic oncology drugs market
- Limited patient awareness and distrust in efficacy of generic oncology drugs reducing market uptake

Exploring Porter’s Five Forces for the Generic Oncology Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Generic Oncology Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Generic Oncology Drugs Market

External macro-environmental factors deeply influence the performance of the Generic Oncology Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Generic Oncology Drugs Market

The Generic Oncology Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Generic Oncology Drugs Market

The Generic Oncology Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Generic Oncology Drugs Market

The Generic Oncology Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Generic Oncology Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Fresenius Kabi AG, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Generic Oncology Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Class
- Alkylating Agents
  - Platinum-Based Drugs
- Monoclonal Antibodies
  - Anti-CD20
  - Anti-CD30
  - Anti-HER2
- Tyrosine Kinase Inhibitors
  - BCR-ABL Inhibitors
  - EGFR Inhibitors
Therapy Type
- Adjuvant Therapy
- Concurrent Chemoradiation Therapy
- Neoadjuvant Therapy
- Palliative Chemotherapy
Cancer Type
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
  - Non-Small Cell Lung Cancer
  - Small Cell Lung Cancer
- Prostate Cancer
Route Of Administration
- Injectable
- Oral
- Topical
End User
- Ambulatory Surgical Centers
- Hospitals
- Oncology Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

What is the current size of the market, and how is it expected to grow?
Which products, segments, and regions present the most attractive investment opportunities?
What are the prevailing technology trends and regulatory factors influencing the market?
How do top vendors rank regarding market share and competitive positioning?
What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
4. Market Overview

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of cancer globally increasing the demand for generic oncology drugs
5.1.1.2. Government initiatives and funding boost for generic cancer drug research and development
5.1.1.3. Escalating healthcare costs drive the shift towards cost-effective generic oncology solutions
5.1.1.4. Increasing patent expiries of blockbuster oncology drugs paving the way for generics transition
5.1.2. Restraints
5.1.2.1. Stringent patent laws and intellectual property challenges hindering generic oncology drug entry
5.1.2.2. Supply chain vulnerabilities and raw material scarcity affecting generic oncology drug production
5.1.3. Opportunities
5.1.3.1. Innovative technologies transforming generic oncology drugs market and enhancing therapeutic outcomes
5.1.3.2. Strategic partnerships and collaborations enhancing research and development in generic oncology medications
5.1.3.3. Regulatory advancements and expedited approval pathways driving growth in the generic oncology sector
5.1.4. Challenges
5.1.4.1. Competition from branded drugs and intellectual property issues impacting the generic oncology drugs market
5.1.4.2. Limited patient awareness and distrust in efficacy of generic oncology drugs reducing market uptake
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental

6. Generic Oncology Drugs Market, by Drug Class

6.1. Introduction
6.2. Alkylating Agents
6.2.1. Platinum-Based Drugs
6.3. Monoclonal Antibodies
6.3.1. Anti-CD20
6.3.2. Anti-CD30
6.3.3. Anti-HER2
6.4. Tyrosine Kinase Inhibitors
6.4.1. BCR-ABL Inhibitors
6.4.2. EGFR Inhibitors

7. Generic Oncology Drugs Market, by Therapy Type

7.1. Introduction
7.2. Adjuvant Therapy
7.3. Concurrent Chemoradiation Therapy
7.4. Neoadjuvant Therapy
7.5. Palliative Chemotherapy

8. Generic Oncology Drugs Market, by Cancer Type

8.1. Introduction
8.2. Breast Cancer
8.3. Colorectal Cancer
8.4. Lung Cancer
8.4.1. Non-Small Cell Lung Cancer
8.4.2. Small Cell Lung Cancer
8.5. Prostate Cancer

9. Generic Oncology Drugs Market, by Route Of Administration

9.1. Introduction
9.2. Injectable
9.3. Oral
9.4. Topical

10. Generic Oncology Drugs Market, by End User

10.1. Introduction
10.2. Ambulatory Surgical Centers
10.3. Hospitals
10.4. Oncology Clinics

11. Americas Generic Oncology Drugs Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Generic Oncology Drugs Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Generic Oncology Drugs Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.4. Strategy Analysis & Recommendation

List of Figures

FIGURE 1. GENERIC ONCOLOGY DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GENERIC ONCOLOGY DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 7. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
FIGURE 11. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 13. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 15. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. GENERIC ONCOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. GENERIC ONCOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

List of Tables

TABLE 1. GENERIC ONCOLOGY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GENERIC ONCOLOGY DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY PLATINUM-BASED DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ANTI-CD20, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ANTI-CD30, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ANTI-HER2, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY BCR-ABL INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ADJUVANT THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CONCURRENT CHEMORADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY NEOADJUVANT THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY PALLIATIVE CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 58. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. ARGENTINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 70. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 71. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 72. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 73. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 74. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 75. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 76. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 77. CANADA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 80. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 81. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 82. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 83. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 84. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 85. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. MEXICO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 97. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 98. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 99. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 100. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 101. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 102. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 103. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 104. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 105. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 107. AUSTRALIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 108. AUSTRALIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 109. AUSTRALIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 110. AUSTRALIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 111. AUSTRALIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 112. AUSTRALIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 113. AUSTRALIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 114. AUSTRALIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. AUSTRALIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 116. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 117. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 118. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 119. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 120. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 121. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 122. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 123. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 126. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 127. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 128. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 129. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 130. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 131. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 132. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. INDIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. INDONESIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 135. INDONESIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 136. INDONESIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 137. INDONESIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 138. INDONESIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 139. INDONESIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 140. INDONESIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 141. INDONESIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 142. INDONESIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 143. JAPAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 144. JAPAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 145. JAPAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 146. JAPAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 147. JAPAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 148. JAPAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 149. JAPAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 150. JAPAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 151. JAPAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. MALAYSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 153. MALAYSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 154. MALAYSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 155. MALAYSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 156. MALAYSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 157. MALAYSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 158. MALAYSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 159. MALAYSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. MALAYSIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. PHILIPPINES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 162. PHILIPPINES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 163. PHILIPPINES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 164. PHILIPPINES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 165. PHILIPPINES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 166. PHILIPPINES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 167. PHILIPPINES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 168. PHILIPPINES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. PHILIPPINES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. SINGAPORE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 171. SINGAPORE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 172. SINGAPORE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 173. SINGAPORE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 174. SINGAPORE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 175. SINGAPORE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 176. SINGAPORE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 177. SINGAPORE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. SINGAPORE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. SOUTH KOREA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 180. SOUTH KOREA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 181. SOUTH KOREA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 182. SOUTH KOREA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 183. SOUTH KOREA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 184. SOUTH KOREA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 185. SOUTH KOREA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 186. SOUTH KOREA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 187. SOUTH KOREA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. TAIWAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 189. TAIWAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 190. TAIWAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 191. TAIWAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 192. TAIWAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 193. TAIWAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 194. TAIWAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 195. TAIWAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. TAIWAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. THAILAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 198. THAILAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 199. THAILAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 200. THAILAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 201. THAILAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 202. THAILAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 203. THAILAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 204. THAILAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 205. THAILAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 206. VIETNAM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 207. VIETNAM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 208. VIETNAM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 209. VIETNAM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 210. VIETNAM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 211. VIETNAM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 212. VIETNAM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 213. VIETNAM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. VIETNAM GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 225. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 226. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 227. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 228. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 229. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 230. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 231. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 232. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. DENMARK GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 235. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 236. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 237. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 238. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 239. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 240. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 241. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 242. EGYPT GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 244. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 245. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 246. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 247. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 248. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 249. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 250. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 251. FINLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 252. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 253. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 254. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 255. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 256. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 257. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 258. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 259. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 260. FRANCE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 261. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 262. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 263. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 264. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 265. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 266. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 267. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 268. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 269. GERMANY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 270. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 271. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 272. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 273. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 274. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 275. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 276. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 277. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 278. ISRAEL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 279. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 280. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 281. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 282. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 283. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 284. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 285. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 286. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 287. ITALY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 289. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 290. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 291. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 292. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 293. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 294. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 295. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 296. NETHERLANDS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 297. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 298. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 299. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 300. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 301. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 302. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 303. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 304. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 305. NIGERIA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 306. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 307. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 308. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 309. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 310. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 311. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 312. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 313. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 314. NORWAY GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 315. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 316. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 317. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 318. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 319. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 320. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 321. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 322. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 323. POLAND GENERIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 324. QATAR GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 325. QATAR GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
TABLE 326. QATAR GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 327. QATAR GENERIC ONCO

Companies Mentioned

The leading players in the Generic Oncology Drugs Market, which are profiled in this report, include:

AbbVie Inc.
Amgen Inc.
AstraZeneca PLC
Bayer AG
Bristol-Myers Squibb Company
Celgene Corporation
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Company
Fresenius Kabi AG
Gilead Sciences, Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Roche Holding AG
Sanofi S.A.
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	195
Published	October 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 38.74 Billion
Forecasted Market Value ( USD ) by 2030	$ 57.97 Billion
Compound Annual Growth Rate	7.0%
Regions Covered	Global
No. of Companies Mentioned	20

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€3382EUR$3,545USD£2,833GBP €3758EUR$3,939USD£3,148GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€5984EUR$6,272USD£5,013GBP €6649EUR$6,969USD£5,570GBP

Understanding Market Dynamics in the Generic Oncology Drugs Market

Exploring Porter’s Five Forces for the Generic Oncology Drugs Market

Applying PESTLE Analysis to the Generic Oncology Drugs Market

Analyzing Market Share in the Generic Oncology Drugs Market

Evaluating Vendor Success with the FPNV Positioning Matrix in the Generic Oncology Drugs Market

Strategic Recommendations for Success in the Generic Oncology Drugs Market

Key Company Profiles

Market Segmentation & Coverage

The report provides a detailed overview of the market, exploring several key areas:

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Europe Branded Generics Market Size, Share & Trends Analysis Report By Drug Class (Alkylating Agents, Antimetabolites), By Application, By Route Of Administration, By Distribution Channel, By Country, And Segment Forecasts, 2023 - 2030

Generic Oncology Drugs Global Market Report 2024

Generic Oncology Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030

U.S. Specialty Injectable Generics Market Size, Share & Trends Analysis Report By Type (Drugs, Biologics), By Application (Oncology, CNS, Cardiovascular), By Distribution Channel (Hospitals, Retail Pharmacy), And Segment Forecasts, 2023 - 2030

Branded Generics Market Size, Share & Trends Analysis By Drug Class (Alkylating Agents, Antimetabolites, Anti-Hypertensive), By Application, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030